April 18, 2022
3 min watch
Save
VIDEO: 'Important developments' in selective estrogen receptor down regulators for patients with ESR1 mutations
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Debu Tripathy, MD, discussed the role of oral selective estrogen receptor down regulators in treating breast cancer patients with ESR1 mutations.
Data regarding outcomes for patients with ESR1 mutations treated with selective estrogen receptor down regulators was reviewed at 39th Miami Breast Cancer Conference.
"It clearly showed an improvement in overall outcome in this group of patients," Tripathy, professor of medicine and chair, department of breast medical oncology at The University of Texas MD Anderson Cancer Center, said.
Published by:
Sources/Disclosures
Collapse
Disclosures:
Disclosures: Tripathy reports receiving institutional research support from Novartis and Pfizer; and serving in consulting roles for AstraZeneca, Exact Sciences, Gilead Sciences, GlaxoSmithKline, Novartis and Pfizer.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.